Table 1.

Baseline characteristics

CharacteristicAll Patients
(n=31)Control Group (n=15)Rituximab Group (n=16)
Age (yr)7.9±4.17.3±3.78.5±4.4
Body weight (kg)31±1730±1731±17
Male, n (%)19 (61)9 (60)10 (62)
Disease duration (yr)1.5 (0.5, 11.8)1.4 (0.5, 8.1)2.5 (0.5, 11.8)
Drug resistance duration (yr)1.3 (0.5, 11.8)0.8 (0.5, 8.1)1.6 (0.5, 11.8)
Delayed resistance, n (%)15 (48)8 (53)7 (44)
Renal histology, n (%)
 not performed4a (13)1 (7)3 (19)
 FSGS19 (61)10 (67)9 (56)
 minimal-change disease7 (23)3 (20)4 (25)
 inadequate material1(3)1(3)
CTX therapy, n (%)10 (32)5 (33)5 (31)
Prednisone dosage (mg/kg per day)0.42 (0.03, 1.9)0.35 (0.03, 1.1)0.51 (0.04, 1.9)
Tacrolimus (vs cyclosporine)16 (15)8 (7)8 (8)
FK506 dosage (mg/kg per day)0.1 (0.05, 0.17)0.1 (0.05, 0.14)0.13 (0.08, 0.17)
Cyclosporine dosage (mg/kg per day)3.6 (2.5, 4.5)3.6 (2.6, 4)3.6 (2.5, 4.5)
ARB or ACEI, n (%)25 (80)11 (73)14 (88)
Urinary protein (g/day per m2)2.7 (0.8, 8.8)2.5 (0.8, 8.8)2.8 (0.8, 6.6)
Serum albumin (g/dl)2.3±0.62.3±0.52.4±0.6
Serum cholesterol (mg/dl)360±143342±129377±158
Serum creatinine (mg/dl)0.54±0.360.55±0.410.53±0.35
IgG (g/dl)322±220324±200320±243
  • Values are means ± SDs or medians (interquartile ranges) reported for quantitative variables (unit) and absolute (relative) frequencies for qualitative variables. CTX, previous use of cytotoxic agents (Endoxan, Leukeran); ARB, angiotensin-receptor blocker; ACEI, angiotensin-converting enzyme inhibitor.

  • a Renal biopsy was not requested in patients who had presented at least one episode of drug responsiveness in the past.